化学性质
| Physical Appearance |
A solid |
| Storage |
Store at -20°C |
| M.Wt |
540.69 |
| Cas No. |
126544-47-6 |
| Formula |
C32H44O7 |
| Solubility |
insoluble in H2O; ?5.8 mg/mL in DMSO; ?0.6 mg/mL in EtOH |
| Chemical Name |
2-((6aR,6bS,7S,8aS,8bS,10R,11aR,12aS,12bS)-10-cyclohexyl-7-hydroxy-6a,8a-dimethyl-4-oxo-2,4,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-2-oxoethyl isobutyrate |
| Canonical SMILES |
CC(C(OCC([C@@]12[C@@](O[C@@](O2)([H])C3CCCCC3)([H])C[C@@]4([H])[C@]([C@]5([H])[C@](O)([H])C[C@@]41C)([H])CCC6=CC(C=C[C@@]65C)=O)=O)=O)C |
| 运输条件 |
蓝冰运输或根据您的需求运输、/td> |
| 一般建?/td> |
为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完、/td> |
资料参耂/h4>
Ciclesonide is a prodrug of the potent glucocorticoid receptor agonist desisobutyryl-ciclesonide. Ciclesonide undergoes the hydrolysis process by ester cleavage at the C21 position to desisobutyryl-ciclesonide, followed by reversible formation of fatty acid esters in lung cells. Although both ciclesonide and desisobutyryl-ciclesonide are able to bind to the glucocorticoid receptor, the active metabolite desisobutyryl-ciclesonide (IC50 = 210 nM) is about 100-fold more potent than the parent compound ciclesonide (IC50 = 1.75 nM). Formulations containing ciclesonide have been used in the maintenance treatment of asthma and in the treatment of allergic rhinitis.
References:
1. Derendorf H, Nave R, Drollmann A, et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. European Respiratory Journal, 2006, 28(5): 1042-1050.
2. Mutch E, Nave R, McCracken N, et al. The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochemical Pharmacology, 2007, 73(10): 1657-1664.
3. Belvisi MG, Bundschuh DS, Stoeck M, et al. Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma. Journal of Pharmacology and Experimental Therapeutics, 2005, 314(2): 568-574.
试验操作
| Cell experiment:[2] |
Cell lines |
Normal human bronchial epithelial (NHBE) cells |
Reaction Conditions |
5 μM ciclesonide for 24 h incubation |
Applications |
Ciclesonide (5 μM) was rapidly hydrolyzed to desisobutyryl-ciclesonide by NHBE cells (approximately 30% conversion within the first 4 h), and 96% conversion of ciclesonide to desisobutyryl-ciclesonide was achieved at 24 h. |
| Animal experiment:[3] |
Animal models |
Ovalbumin-sensitized and challenged Brown Norway rats |
Dosage form |
0 ~ 10 mg/kg Administered by the intratracheal route into the airways 24 and 1 h before exposure to inhaled antigen |
Applications |
Ciclesonide dose-dependently suppressed the antigen-induced influx of eosinophils into the airway lumen, with an ED50 value of 0.75 mg/kg. Moreover, ciclesonide significantly inhibited eosinophil influx into the lung tissue, with an ED50 value of 0.49 mg/kg. |
Note |
The technical data provided above is for reference only. |
|
References: 1. Derendorf H, Nave R, Drollmann A, et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. European Respiratory Journal, 2006, 28(5): 1042-1050. 2. Mutch E, Nave R, McCracken N, et al. The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochemical Pharmacology, 2007, 73(10): 1657-1664. 3. Belvisi MG, Bundschuh DS, Stoeck M, et al. Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma. Journal of Pharmacology and Experimental Therapeutics, 2005, 314(2): 568-574. |
m.cnreagent.com
